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Experimental Type 2 Diabetes Induces Enzymatic Changes
in Isolated Rat Enterocytes
Isabel M. Mart´ ınez, Inmaculada Morales, Guadalupe Garc´ ıa-Pino,
Jos´ e E. Campillo, and Mar´ ıa A. Tormo
Departamento de Fisiolog´ ıa, Facultad de Medicina, Universidad de Extremadura, Badajoz, Spain
Diabetes in humans and in experimental animals
produces changes in the function and structure of the
small intestine. The authors determined the activity of
intestinal disaccharidases (maltase and sucrase) and of
6-phosphofructo-1-kinase (PFK-1) in enterocytes isolated
fromthesmallintestineofmaleWistarrats(2.5to3months
old)withexperimentalnonobesetype2diabetes,inducedby
streptozotocin (STZ) injection on the day of birth (n0-STZ)
or on the 5th day of life (n5-STZ), with different degrees
of hyperglycemia and insulinemia (n0-STZ and n5-STZ
models). The glycemia (mmol/L) of the diabetic rats
(n0-STZ: 8.77±0.47; n5-STZ: 20.83±0.63) was higher
(P <.01) than that of the nondiabetic (ND) rats
(5.99±0.63); on the contrary, the insulinemia (ng/mL) was
signiﬁcantly lower in both n0-STZ (1.74±0.53; P <.05)
andn5-STZ(1.12±0.44; P <.01)diabeticratsthaninnor-
mal rats (3.77±0.22). The sucrase and maltase activities
(U/gprotein)indiabeticrats(n0-STZ:89±9and266±12;
n5-STZ: 142±23 and 451±57) were signiﬁcantly higher
than those in the ND group (66±5 and 228±22). The
PFK-1 activities (mU/mg protein) in the diabetic models
(n0-STZ: 14.89±1.51; n5-STZ: 13.35 ± 3.12) were signif-
icantly lower (P <.05) than in ND rats (20.54±2.83). The
datademonstratedenzymaticalterationsinenterocytesiso-
latedfromthesmallintestineofn0-STZratsthataregreater
(P <.05)thaninthemorehyperglycemicandhypoinsuline-
mic n5-STZ animals. The results also show that nonobese
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type 2–like diabetes in the rat produces modiﬁcations that
favor an increase in glucose absorption rates.
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In humans and in experimental animals, diabetes produces
changes in the function and structure of the small intestine,
including increased glucose transport [1, 2], increased spe-
ciﬁc and total disaccharidase activity [3–6], and changes in
6-phosphofructo-1-kinase activity [7, 8]. All these alterations
cancontributetotheappearanceofpostprandialhyperglycemic
peaks,andconsequentlytothedevelopmentofthechroniccom-
plications of diabetes.
Most studies demonstrating the inﬂuence of diabetes on the
intestine have been performed in models of diabetes induced in
adult experimental animals by the administration of alloxan or
streptozotocin (STZ). This leads to a diabetes similar to type 1
in man, with a complete absence of plasma insulin and extreme
hyperglycemia. There are few data, however, from other dia-
betes models characterized by glycemia levels not as high as
those in type 1 diabetes and by a wide range of plasma insulin
levels. The exact mechanisms of these enzymatic alterations in
diabetes are unknown, but some studies on animals with exper-
imental type 1 diabetes have suggested that the hyperglycemia
[9] might in part be responsible for an increased disaccharidase
activity, which is reduced after insulin treatment [2].
Given this situation, our purpose was to study the activity of
theintestinaldisaccharidasesandof6-phosphofructo-1-kinase,
in enterocytes isolated from the small intestine of 2 rat models
of nonobese type 2 diabetes with different degrees of hyper-
glycemia and insulinemia.
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MATERIALS AND METHODS
Experimental Animals
We used male Wistar rats, fed a standard commercial
diet (maintenance diet Letica, Panlab S.L., Barcelona, Spain;
61.41% w/w carbohydrate, 3.96% ﬁber, 15.06% protein, and
2.66% fat). The rats had free access to water and food. They
were housed in the animalarium of the University of Ex-
tremadura at room temperature (24◦C±2◦C), with lighting
from 08:00 to 20:00 hours. The animals were cared for in ac-
cordance with the principles of the Guide for Care and Use of
Experimental Animals.
Induction of Experimental Diabetes
We generated 2 models of experimental diabetes, known
as neonatal diabetes, by STZ (Sigma-Aldrich Qu´ ımica S.A.,
Alcobendas, Madrid, Spain) treatment, as previously described
[10, 11]. The n0-STZ model was obtained by a single dose of
STZ (100 mg/kg body weight [bw]) dissolved in citrate buffer
(0.1mol/L)atpH4.5,administeredintraperitoneallyontheday
of birth. The n5-STZ model was induced by a single dose of
STZ (80 mg/kg bw) on day 5 after birth. The nondiabetic (ND)
control rats received only the citrate buffer, intraperitoneally.
At the age of 2.5 months, the body weight and glycemia were
measured and an oral glucose tolerance test was performed
in all groups. Blood samples were obtained from a cut made
at the tip of the animal’s tail, and blood glucose was immedi-
atelyassayedusingaglucometerandreactivestrips(Glucocard
Memory; A. Menarini Diagnostics, San Adri´ an del Bes´ os,
Barcelona, Spain). The rest of the blood was collected into pre-
heparinized Eppendorff tubes, and the plasma was separated
by centrifugation and stored at −70◦C until immunoreactive
insulin (IRI) assays were performed.
Oral Glucose Tolerance Test
After 18 hours’ fasting, all the groups (normal, n0-STZ dia-
betic, and n5-STZ diabetic rats) were subjected to an oral glu-
cose (0.5 g/kg bw) tolerance test. First a blood sample was
taken (time 0), and then glucose was administered via a gastric
cannula (0.5 g/kg bw, as a 50% solution in 0.9% NaCl), with
the animal awake. Blood samples were taken at the times indi-
cated in Figure 1. Incremental areas under the curves (AUCs)
of glucose and insulin were determined by planimetry. Insulin
was determined by radioimmunoassay with a rat insulin kit
that uses a speciﬁcally synthesized antibody against rat in-
sulin (DRG’s Instrument GmbH, Marburg, Germany). Only
those diabetic animals presenting a clear oral glucose intol-
erance were selected to form part of the diabetic groups in the
study.
Isolation of Enterocytes and Assay Methods
The disaccharidases (sucrase and maltase) and 6-
phosphofructo-1-kinase (PFK-1) activities were determined in
enterocytes isolated from the complete small intestine follow-
ing the method previously described [12]. In brief, the rat was
killed by a pentobarbital overdose. The abdomen was cut open,
and the small intestine was removed, rinsed with 20 mL of
0.9% NaCl, blotted dry, weighed, and measured under 5-g ten-
sion. Enterocytes were then isolated by a method that allows
the isolation of metabolically competent enterocytes, based on
an EDTA and gentle mechanical treatment of the small intes-
tine mucosa. The disaccharidase activity was determined by
the technique of Dahlqvist [13]. PFK-1 activity was measured
under maximum-rate conditions by the technique of Kitajima
and Uyeda [14]. Protein concentration was determined by the
micro-Lowry method (Sigma-Aldrich Qu´ ımica S.A.), using
bovine albumin as standard.
The results are expressed as means with their corresponding
standard errors of measurement (SEM). The statistical analysis
used the Mann-Whitney U test for independent samples.
RESULTS
Table 1 lists the general characteristics of the experimen-
tal animals. In adulthood, the n0-STZ and n5-STZ rats pre-
sented hyperglycemia, which was signiﬁcantly greater in the
n5-STZ than in the n0-STZ rats. Insulin values were signiﬁ-
cantly lower in both diabetes models than in the controls. The
body weight was similar between the n0-STZ diabetic rats and
the controls, but was lower (P <.01) in the n5-STZ group. The
weight and length of the small intestine, however, were signif-
icantly greater in the 2 diabetes models than in the controls;
TABLE 1
General characteristics of nondiabetic (ND) and n0-STZ and
n5-STZ diabetic rats measured at age 2.5 months
ND n0-STZ n5-STZ
Blood glucose 5.99±0.07 8.77±0.47∗∗ 20.83±0.63∗∗aa
(mmol/L)
Plasma insulin 3.77±0.22 1.74±0.53∗ 1.12±0.44∗∗
(ng/mL)
Body weight 367±13 390±12 250±33∗∗aa
(g)
Small intestine 8.57±0.19 10.97±0.72∗ 18.25±0.72∗∗aa
weight (g)
Small intestine 108±1 118±2∗ 144±5∗∗aa
length (cm)
Note. Values are the mean±SEM for 6 animals for each group.
∗P <.05; ∗∗P <.01 compared to ND rats; aaP <.01 compared to
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FIGURE 1
Glycemia (mmol/L) and insulinemia (ng/mL) measured during an oral glucose tolerance test after 18 hours of fasting, given to
nondiabetic (ND) and n0-STZ and n5-STZ diabetic rats. Values are the mean±SEM for 6 animals for each group.
and both parameters were signiﬁcantly greather (P <.01) in
the n5-STZ versus the n0-STZ rats.
The development of diabetes in the n0-STZ and n5-
STZ rats was conﬁrmed by the oral glucose tolerance test
(Figure 1). Oral administration of glucose led to a signiﬁcant
increase of the blood glucose AUC (mmol/L·120 min) in both
the n0-STZ model (600±23; P <.05) and the n5-STZ model
(592±77; P <.05) with respect to the ND group (204±16).
These changes were accompanied by a lower insulin secretion
response (plasma insulin AUC: ng/mL·120 min) in the 2 di-
abetes models (n0-STZ: 13±2; n5-STZ: 8±2; P <.05) with
respect to the ND group (60±14).
As shown in Figure 2, the speciﬁc activities of sucrase
and maltase in the n0-STZ (89±9 and 266±12 U/g protein)
and n5-STZ (142±23 and 451±57 U/g protein) diabetic rats
were signiﬁcantly higher than those in ND rats (66±5 and
228±22 U/g protein). Also, the enterocyte enzymatic activi-
ties were higher in the n5-STZ than in the n0-STZ diabetic rats
(P <.05).
Figure3showsthePFK-1speciﬁcactivitymeasuredinenter-
ocytes isolated from the small intestine of the 3 groups of rats.
Thevalues(mU/mgprotein)weresigniﬁcantlylower(P <.05)
in the diabetic (n0-STZ: 14.89±1.51; n5-STZ: 13.35±3.12)
than in the ND (20.54±2.83) rats.122 I. M. MART´ INEZ ET AL.
FIGURE 2
Sucrase and maltase activities (U/g protein) measured in
enterocytes isolated from ND and n0-STZ and n5-STZ
diabetic rats. Values are the mean±SEM for 6 animals for
each group. ∗P <.05 and ∗∗P <.01 versus ND rats; aP <.05.
DISCUSSION
For the present study, we used 2 models of nonobese type
2–like diabetes, induced by the intraperitoneal STZ adminis-
tration in the neonatal period (n0-STZ and n5-STZ models).
These models had been developed and thoroughly investigated
by Portha and coworkers [10, 11, 15, 16]. They showed that
defects in insulin secretion and action develop in the n-STZ
models, and that these defects in many ways resemble those
described in humans. Nevertheless, there have been no studies
on how the intestinal function is affected. We found that the
length and weight of the small intestine were increased in those
2 models of diabetes. This is in agreement with results that
we had previously obtained in n0-STZ diabetic rats [17], and
FIGURE 3
6-Phosphofructo-1-kinase activity measured in enterocytes
isolated from ND and n0-STZ and n5-STZ diabetic rats.
Values are the mean±SEM for 6 animals for each group.
∗P <.05 versus ND rats.
withtheresultsofothermodelsofSTZ-inducedtype1diabetes
that show hypertrophy of the small intestine mucosa as well as
other alterations [18, 19]. The etiology of these morphological
alterations is, however, still an issue of debate [20, 21].
It is well known that speciﬁc and total activities of the di-
saccharidasesareincreasedinthemucosaofthesmallintestine
of diabetic animals [4–6, 9] and diabetic patients [3]. This con-
tributestotheincreaseintherateofglucoseabsorptionobserved
both in humans and in animal type 1 diabetes models, and jus-
tiﬁes the pharmacological use of intestinal alpha-glucosidase
inhibitorsinthetreatmentofdiabetes.Ourresultsindiabetican-
imalmodelsareconsistentwiththestudiesthatreportincreased
intestinal disaccharidase activities in type 1 diabetic animals.
Wehavealsofoundanincreaseinsucraseandmaltaseactivities
measuredintheproximalintestinemucosascrapingsofn0-STZ
diabetic rats [17]. Caspary and colleagues [2] describe a rever-
sal or depression of this increase following insulin treatment.
Murakami and Ikeda [9] concluded that hyperglycemia is par-
tially responsible for the increased disaccharidase activities in
diabetes. Our results support the conclusions of Murakami and
Ikeda [9], because the increase in disaccharidase activity was
greater in the enterocytes from the n5-STZ diabetic rats, which
presented a greater degree of hyperglycemia and lower insu-
linemia than the enterocytes isolated from the n0-STZ diabetic
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Other enzymatic alterations have also been observed in the
diabeticintestine.Ratswithinsulin-deﬁcientdiabeteshavebeen
reportedtohavereducedPFKactivityintheproximalintestinal
mucosa [8] and in enterocytes isolated from the small intestine
[7]. We also have found a reduction in PFK-1 activity in the
proximal and distal intestinal homogenates of n0-STZ diabetic
rats[17].Theseresultsareinagreementwiththoseofthepresent
work with enterocytes isolated from the n0-STZ diabetic rats,
where the reduction in PFK-1 activity was 27%, and from the
n5-STZ diabetic rats, where the reduction was 35%. In princi-
ple,suchareductioninPFKactivitycouldreducetheutilization
ofglucosebythesmallintestineinratmodelsoftype1diabetes
[22, 23], thus contributing to a postprandial hyperglycemia in
diabetes.
The effect of diabetes on enzymatic activities and glucose
transport has been attributed to hyperglycemia [9], hypoinsu-
linemia [2], or both. Although the present work was not aimed
at studying mechanisms, the results do suggest that the great-
est effects are obtained in the most hyperglycemic and most
hypoinsulinemic rats.
Our study shows the appearance of enzymatic alterations
in enterocytes isolated from 2 models of nonobese type 2
diabetes in rats (n0-STZ and n5-STZ). It also shows that
such diabetes produces modiﬁcations that favor an increase in
glucose absorption rates. The small intestine enzymatic alter-
ations are more pronounced in n5-STZ than in n0-STZ diabetic
rats.
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